COPENHAGEN, Denmark I March 17, 2025 I Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

A degrader molecule, either PROTAC or molecular glue, brings the protein of interest (POI) and E3 ubiquitin ligase in close proximity and engages the ubiquitin-proteasome system (UPS), the cellular ...

Peripartum cardiomyopathy (PPCM) program: First-in-human dosing with BHV-1600, a TRAP degrader of β1AR autoantibodies, was initiated and has been well-tolerated to date after the first two dosing ...

Biohaven's unique extracellular degrader technology leverages the body's natural hepatic clearance mechanism to remove targeted antibodies contributing to disease and promises to usher in a new ...

Each EpiTAC has both a target protein–binding arm and a degrader receptor–binding arm. Unlike PROTACs—which use small molecules to degrade proteins inside cells—EpiTAC antibodies can ...

How did A compare to I, when they each combined with V. The A combination was worse in ... 500 patients and is by far the most advanced BTK degrader. We presented compelling early efficacy and ...

reinforced by the continued success of BRUKINSA and the development of one of the most prolific solid tumor pipelines in oncology with multiple data readouts expected this year,” said John V.

School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China ...

Two papers in Nature now reveal that a glue degrader and cancer mutations enable an E3 ligase to recognize the same target protein through a convergent binding mode, which could inform discovery ...